Creation of start-up BrightSens Diagnostics

BrightSens Diagnostics, created in January 2022 by Andrey Klymchenko, Andreas Reich & John Volke, is the result of research on fluorescent nanoparticles conducted in LBP in the team Nanochemistry and Bioimaging.

The start-up aims to develop a new generation of molecular assays for screening, diagnosis and patient monitoring. Since the end of 2020 BrightSens Diagnostics has been incubated at Sémia. Its mirSens project, focused on the detection of microRNAs as cancer biomarkers, is a winner of the iLab 2021 innovation competition.

For more information :